Introduction {#section5-0269881119826783}
============

Agomelatine is a first in class antidepressant that acts via the stimulation of melatonin (MT~1~/MT~2~) receptors and antagonism of serotonin (5-HT)~2C~ receptors, most notably in the suprachiasmatic nucleus of the hypothalamus ([@bibr13-0269881119826783]). By virtue of this action, it acts predominantly to re-entrain altered circadian rhythms, thereby exerting a chronobiotic action ([@bibr42-0269881119826783]). Early-life adversity is a causal factor in the development of an anxiety disorder later in life ([@bibr5-0269881119826783]; [@bibr15-0269881119826783]). Recently we confirmed this construct in post-weaning social isolation reared (SIR) rats, while furthermore describing the anxiolytic-like effects of agomelatine in this neurodevelopmental model of anxiety ([@bibr43-0269881119826783]). We found this model to be associated with significant late-life anxiety-related behavior in both sexes, while at the same time demonstrating a significant reduction in plasma corticosterone, also in both sexes. Reduced corticosterone (in rodents) or cortisol (in humans) is a pathological feature of anxiety-like behavior, e.g. in posttraumatic stress disorder (PTSD) ([@bibr27-0269881119826783]), possibly related to overt suppression of the hypothalamic-pituitary-adrenal (HPA) axis ([@bibr27-0269881119826783]). However, a rather unexpected finding in our study was that, despite the anxiolytic-like properties of agomelatine in this model, it failed to reverse reduced corticosterone ([@bibr43-0269881119826783]). This observation suggests that reduced corticosterone is not a major contributing factor to SIR-related anxiety, and/or that agomelatine's anxiolytic-like actions involve another mechanism, at least in this model.

Vasopressin and oxytocin are gaining increasing importance with respect to anxiety, stress-coping and sociality ([@bibr36-0269881119826783]). Importantly, central oxytocin exerts anxiolytic and antidepressant effects, whereas vasopressin tends to show anxiogenic and depressive actions ([@bibr36-0269881119826783]). Altered circadian fluctuation of these neuropeptides has been described in chronic anxiety states, especially vasopressin ([@bibr20-0269881119826783]; [@bibr30-0269881119826783]). Oxytocin and vasopressin have shown sex-specific effects in animal models ([@bibr3-0269881119826783]). However, there is a paucity of data in female animals ([@bibr18-0269881119826783]; [@bibr47-0269881119826783]), which is problematic considering that stress-induced mental disorders, including PTSD, are two to three times more prevalent in females than in males ([@bibr38-0269881119826783]). In anxiety-related conditions specifically, oxytocin exerts contrasting sex-dependent effects on amygdala activity ([@bibr8-0269881119826783]) while for vasopressin prenatal stress-induced social memory deficits are more prominent in females than males, with vasopressin-1a receptor mRNA expression in the lateral septum and bed nucleus of stria terminalis unaltered in males but significantly lower in females ([@bibr12-0269881119826783]). In a stress-induced depression model, [@bibr21-0269881119826783] also showed that stress-regulated transcriptional changes in the hypothalamus are sex-specific and ovarian hormone-dependent.

Considering agomelatine's chronobiotic actions to re-entrain disordered circadian hormones, such as cortisol and melatonin ([@bibr7-0269881119826783]; [@bibr25-0269881119826783]), and that it presents with clinically relevant anxiolytic activity ([@bibr4-0269881119826783]), we pondered the question whether vasopressin and oxytocin may underlie the earlier observed anxiolytic-like actions of agomelatine in SIR rats, perhaps more so than corticosterone, and whether any sex specific effects are evident.

Subjects and methods {#section6-0269881119826783}
====================

A total of 72 Sprague--Dawley rats (36 males and 36 females) were provided by the Vivarium of the North-West University (NWU). Animals were bred and housed at the Vivarium (South African Veterinary Council reg. number FR15/13458; South African National Accreditation System good laboratory practice compliance number G0019) of the Pre-Clinical Drug Development Platform of the NWU. All experiments were ethically approved (National Health Research Ethics Council reg. number AREC-130913-015) to comply with the Animal Research: Reporting In Vivo Experiments (ARRIVE) guidelines ([@bibr22-0269881119826783]) as well as the code of ethics in research, training and testing of drugs in South Africa (ethics approval number NWU-00347-15-S5).

Using the social isolation rearing protocol described previously ([@bibr43-0269881119826783]), animals were randomized post weaning (post-natal day (PND) 21) to either social isolation rearing (one animal per cage) or social rearing (three animals per cage) for eight weeks (PND 77) ([@bibr31-0269881119826783], [@bibr32-0269881119826783]). Groups consisted of 12 rats per group, with male and female rats housed separately but in the same room. Housing conditions were as described by [@bibr43-0269881119826783]. Since regular handling reduces the effects of social isolation rearing ([@bibr10-0269881119826783]; [@bibr48-0269881119826783]), vaginal smears for documenting the specific estrous cycle of females was not performed.

Social and isolation reared animals received sub-chronic treatment with vehicle (1% hydroxyethylcellulose (HEC)) or agomelatine (Servier, Suresnes, France; 40 mg/kg/day), the latter freshly prepared in 1% HEC suspension (pH=6.4). Agomelatine or vehicle were administered intraperitoneally (i.p.) at 16:00 each day ([@bibr2-0269881119826783]) in a total injection volume of 1 mL/kg for 16 days from PND 61 ([@bibr31-0269881119826783], [@bibr32-0269881119826783]). The dosage regimen for agomelatine was derived from earlier studies suggesting its antidepressant-like and anxiolytic-like actions are best captured in rodents when administered in the late afternoon and at the above-noted dose and duration of treatment ([@bibr2-0269881119826783]; [@bibr37-0269881119826783]; [@bibr40-0269881119826783]; [@bibr43-0269881119826783]). Since agomelatine failed to alter behavior in socially reared control rats ([@bibr6-0269881119826783]) and to conserve animals, this group was not included in the study (see also [@bibr43-0269881119826783]).

On the last day of drug treatment (PND 78), rats were euthanized (at 08:00--09:00) with no prior anesthesia. Trunk blood was collected in pre-chilled, 4 mL vacutainer tubes (SGVac) containing dipotassium ethylenediaminetetraacetic acid (K2EDTA) solution as anti-coagulant. The blood was centrifuged at 20,000× *g* at 4°C for 10 min and the plasma stored at −80°C. On the day of analysis, plasma samples were thawed on ice, centrifuged again as described above, and the plasma used for the analysis of corticosterone, vasopressin, and oxytocin. Plasma corticosterone was quantified using a solid-phase extraction (SPE) high-performance liquid chromatography (HPLC) method, as described previously ([@bibr43-0269881119826783]). Plasma vasopressin and oxytocin were assayed using enzyme-linked immunosorbent assay (ELISA) (Arg8-Vasopressin ELISA Kit Catalog No: ab205928, Abcam; Oxytocin ELISA Kit Catalog No: E-EL-0029, Elabscience)

Selected behavioral data for correlation analysis {#section7-0269881119826783}
=================================================

The relationship between anxiety-like behavior as reported previously ([@bibr43-0269881119826783]) and plasma oxytocin, vasopressin, and corticosterone levels was determined. Although we had previously performed a diverse range of anxiety tests in SIR animals receiving agomelatine or vehicle (see [@bibr43-0269881119826783]), the correlation analysis undertaken here used only percentage time in open arms (TOA) as reference anxiety parameter. Briefly, anxiety-like behavior was assessed in the elevated plus maze (EPM; *n*=12/group) within the first two hours of the dark cycle (18:00--20:00) on PND 76, three hours after the last dose of agomelatine ([@bibr43-0269881119826783]. Behavior was scored by Noldus EthoVision XT 12 under dim white light (10 lux) conditions ([@bibr16-0269881119826783]; [@bibr35-0269881119826783]) and expressed as percentage TOA. Arm entries were scored only when all four paws entered the arm.

Statistical analysis {#section8-0269881119826783}
====================

Graphpad Prism version 6 for Windows (Graphpad Software, San Diego, USA) was used for all statistical analysis and graphical presentations. Normality of the data was determined using the Shapiro-Wilk test. Data were analyzed by two-way analysis of variance (ANOVA) with respect to sex and treatment to determine the anxiolytic-like effects of agomelatine. Where an interaction and/or simple main effect were found in the ANOVA analysis, this was followed by a Bonferroni post-hoc analysis or an unpaired student's *t*-test. In all cases, data are expressed as the mean±standard error of the mean, with a *p* value of \<0.05 deemed statistically significant. The correlation between corticosterone, vasopressin, oxytocin, and percentage TOA was determined using Pearson's rank correlation in all treatment groups. Pearson's correlation coefficient (*r*) was defined as 0.1⩽*r*\<0.3 indicating a small effect, 0.3⩽*r*\<0.5 a medium effect, and *r*⩾0.5 a large effect. A probability level of 95% was used to determine statistical significance (*p*\<0.05).

Results {#section9-0269881119826783}
=======

Effect of social isolation rearing with/without agomelatine treatment on plasma corticosterone and neuropeptide levels {#section10-0269881119826783}
----------------------------------------------------------------------------------------------------------------------

[@bibr43-0269881119826783] described a significant anxiogenic effect for social isolation rearing in female and male rats, evinced as decreased percentage TOA (amongst other anxiety-related behaviors) with an associated hypocortisolemia. Agomelatine treatment reversed anxiety in both female and male SIR rats but not hypocortisolemia ([@bibr43-0269881119826783]). We have now re-analyzed the percentage TOA and corticosterone data presented in [@bibr43-0269881119826783] ([Table 1](#table1-0269881119826783){ref-type="table"} and [Figure 1(a)](#fig1-0269881119826783){ref-type="fig"} respectively), while in addition introducing novel analysis of plasma oxytocin and vasopressin.

###### 

Pearson correlation matrix depicting associations between oxytocin, vasopressin, corticosterone, and percentage time in open arms (%TOA) across all treatment groups (male and female) (*n*=72; 12 rats/group).

![](10.1177_0269881119826783-table1)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                               Vasopressin                Oxytocin                  Corticosterone            %TOA
  ---------------------------------------------------------------------------- -------------------------- ------------------------- ------------------------- --------------------------
  **Vasopressin**                                                              \-                         −0.45 (−0.24 -- −0.62)\   −0.55 (−0.37 -- −0.69)\   −0.26 (−0.034 -- −0.47)\
                                                                                                          *p*\<0.0001               *p*\<0.0001               *p*=0.025

  **Oxytocin**                                                                 −0.45 (−0.24 -- −0.62)\    \-                        0.31 (0.51--0.008)\       NS
                                                                               *p*\<0.0001                                          *p*=0.007                 

  **Corticosterone** ^[a](#table-fn2-0269881119826783){ref-type="table-fn"}^   −0.55 (−0.37 -- −0.69)\    0.31 (0.51--0.008)\       \-                        NS
                                                                               *p*\<0.0001                *p*=0.007                                           

  **%TOA**                                                                     −0.26 (−0.034 -- −0.47)\   NS                        NS                        \-
                                                                               *p*=0.025                                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval; NS: non-significant.

Data from [@bibr43-0269881119826783] re-presented and re-analyzed.

![Plasma levels of (a) corticosterone, (b) oxytocin, and (c) vasopressin respectively in socially reared animals receiving vehicle treatment and social isolation reared (SIR) animals receiving vehicle and agomelatine treatment, presented as mean±standard error of the mean (SEM) (*n*=12 rats/group). \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001, \*\*\*\**p\<*0.0001 vs social vehicle; \#*p*\<0.05 vs SIR vehicle (two-way analysis of variance (ANOVA), Bonferroni's post-hoc analysis); \^*p*\<0.05 vs SIR vehicle (unpaired student's *t*-test).](10.1177_0269881119826783-fig1){#fig1-0269881119826783}

A two-way ANOVA revealed no significant gender×treatment interaction on corticosterone (*F*(2,65)=0.07, *p*=0.9). However, a significant main effect regarding gender on corticosterone levels was observed (*F*(1,65)=7.46, *p*=0.008) and a significant treatment effect (*F*(2,65)=20.13, *p*\<0.0001). Two-way ANOVA indicated no significant gender×treatment interaction with respect to oxytocin (*F*(2,66)=0.02, *p*=0.97) and vasopressin (*F*(2,66)=0.5, *p*=0.59). Unlike with corticosterone, gender had no significant main effect on oxytocin (*F*(1,66)=0.59, *p*=0.44) or vasopressin (*F*(1,66)=2.01, *p*=0.16). However, treatment had a significant main effect on oxytocin (*F*(2,66)=24.59, *p*\<0.0001) and vasopressin (*F*(2,66)=8.35, *p*=0.0006).

Social isolation rearing significantly decreased plasma corticosterone in both females (*p*=0.0002) and males (*p*=0.001), while agomelatine did not reverse this affect ([@bibr43-0269881119826783]) ([Figure 1(a)](#fig1-0269881119826783){ref-type="fig"}). Social isolation rearing significantly decreased plasma oxytocin in both females and males (*p*\<0.0001) ([Figure 1(b)](#fig1-0269881119826783){ref-type="fig"}) and significantly increased plasma vasopressin in females (*p*=0.01) and males (*p*=0.003) ([Figure 1(c)](#fig1-0269881119826783){ref-type="fig"}). Agomelatine significantly reversed elevated vasopressin in both females (*p*=0.03) and males (*p*=0.01) ([Figure 1(c)](#fig1-0269881119826783){ref-type="fig"}). Although not significant in the two-way ANOVA, agomelatine partially reversed reduced oxytocin levels in females (*p*=0.03) but not in males (*p*=0.07) ([Figure 1(b)](#fig1-0269881119826783){ref-type="fig"}; unpaired student's *t*-test).

Correlation analyses were performed in the combined dataset of all the female and male drug-treated groups (*n*=72) ([Table 1](#table1-0269881119826783){ref-type="table"}). No noteworthy correlations were evident in the separate groups. Considering the cross-correlation neuropeptide analysis, significant negative correlations were observed between vasopressin and oxytocin (Pearson's *r*=−0.45, *p*\<0.0001) and between vasopressin and corticosterone (Pearson's *r*=−0.55, *p*\<0.0001), while a significant positive correlation was evident with respect to oxytocin and corticosterone (Pearson's *r*=0.31, *p*=0.007). Considering the neuropeptide-anxiety correlation, vasopressin levels and percentage TOA showed a significant negative correlation (Pearson's *r*=−0.26, *p*=0.025) ([Table 1](#table1-0269881119826783){ref-type="table"}), and depicted specifically in [Figure 2](#fig2-0269881119826783){ref-type="fig"}. Oxytocin (Pearson's *r*=0.22, *p*=0.08) and corticosterone (Pearson's *r*=0.23, *p*=0.07) narrowly missed a significant correlation with percentage TOA.

![Pearson correlation analysis between percentage time in open arms (%TOA) and plasma vasopressin in all treatment groups (male and female) (*n*=72).](10.1177_0269881119826783-fig2){#fig2-0269881119826783}

Discussion {#section11-0269881119826783}
==========

Early life adversity (e.g. social isolation rearing) exerts profound neurodevelopmental effects that alter 5-HT as well as other neurotransmitters, culminating in late-life presentation of anxiety, depression and antisocial behavior ([@bibr5-0269881119826783]; [@bibr10-0269881119826783]; [@bibr15-0269881119826783]; [@bibr34-0269881119826783]). 5-HT~1A~ and 5-HT~2A~ receptors are expressed in the rat brain from gestational day (GD) 16 ([@bibr41-0269881119826783]) and PND 3 ([@bibr26-0269881119826783]), respectively, and may be compromised by an early-life neurodevelopmental challenge ([@bibr28-0269881119826783]; [@bibr29-0269881119826783]). Indeed, earlier work has noted that social isolation rearing significantly alters regional brain 5-HT levels ([@bibr33-0269881119826783]; [@bibr45-0269881119826783]). Although 5-HT reuptake inhibitors (SSRIs) may offer effective treatment, full remission in anxiety ([@bibr44-0269881119826783]) and mood ([@bibr9-0269881119826783]) disorders is seldom attained, emphasizing the need to identify new biological targets as well as drug treatments. In this regard, disturbed circadian rhythm is a recognized contributor to these disorders ([@bibr42-0269881119826783]), with chronobiotic agents like agomelatine offering hope for more effective pharmacotherapy.

Both animal and human studies suggest that plasma vasopressin levels correlate with anxiety in adulthood ([@bibr46-0269881119826783]). To the best of our knowledge, this is the first study to investigate concomitant changes in corticosterone, vasopressin and oxytocin following social isolation rearing in rats and their association with anxiety-like behavior. Here we report that rearing condition, i.e. be it group- or isolation-housed, engenders a significant and negative correlation between anxiety and plasma vasopressin. Thus, social isolation rearing is associated with reduced %TOA and elevated plasma vasopressin. Although social isolation rearing significantly decreased plasma oxytocin levels, the association between anxiety and plasma oxytocin was insignificant in all the treatment groups. Given the anxious state of these animals ([@bibr43-0269881119826783]), these findings support the anxiogenic role of vasopressin in mediating anxious states, less so the anxiolytic actions of oxytocin ([@bibr36-0269881119826783]). Similarly, although significant hypocortisolemia was evident in SIR animals ([@bibr43-0269881119826783]), the correlation between anxiety and plasma corticosterone was insignificant in all the treatment groups.

This and our earlier work ([@bibr43-0269881119826783]) provides unequivocal evidence that post-weaning social isolation rearing induces anxiety-like behavior later in life, as well as reduces plasma corticosterone and oxytocin but elevates vasopressin. Moreover, we corroborate the probable causal association of SIR-induced anxiety with increased vasopressin rather than with reduced corticosterone or oxytocin. The interactive nature of these neuropeptides is important to consider here. Indeed, a medium effect size negative correlation was observed between vasopressin and oxytocin, as well as a large effect size negative correlation between vasopressin and corticosterone. On the other hand, we observed a medium effect size positive correlation between oxytocin and corticosterone. The significant negative correlation between vasopressin and oxytocin confirms earlier findings within the context of anxiety ([@bibr36-0269881119826783]). However, corticotrophin-releasing hormone (CRH) (and its subsequent activation of glucocorticoid release) and vasopressin are the central drivers of the stress hormone system ([@bibr17-0269881119826783]). The negative correlation between vasopressin and corticosterone thus appear counter-intuitive with respect to the genesis of anxiety. Oxytocin on the other hand plays a moderating role on bio-behavioral responses to stress ([@bibr49-0269881119826783]). Since we observed a positive correlation between oxytocin and corticosterone, it is interesting that elevated oxytocin reduces stress-induced corticosterone release ([@bibr50-0269881119826783]). Given the juxtaposed findings noted with regard to vasopressin and oxytocin vs. corticosterone, we posit that under extended stressful conditions (e.g. social isolation rearing) certain inherent protective mechanisms are compromised resulting in an anxiogenic response.

5-HT plays an important role in regulating the release of the above hormones ([@bibr19-0269881119826783]; [@bibr39-0269881119826783]), which as noted earlier may be compromised by social isolation rearing ([@bibr33-0269881119826783]; [@bibr45-0269881119826783]). Thus, the serotonergic system plays a key role in the anxiolytic effects of oxytocin ([@bibr51-0269881119826783]), with 5-HT-induced oxytocin secretion mediated by 5-HT~1A~ (inhibitory) and 5-HT~2A/C~ (excitatory) receptors ([@bibr19-0269881119826783]) in the paraventricular nucleus (PVN) ([@bibr52-0269881119826783]). 5-HT also stimulates vasopressin release at the neurohypophyseal level ([@bibr24-0269881119826783]) via 5-HT~2C~, 5-HT~4~, and 5-HT~7~ receptor activation ([@bibr19-0269881119826783]) while, conversely, vasopressin can promote the synthesis and release of 5-HT in the hippocampus ([@bibr1-0269881119826783]). With agomelatine significantly reversing SIR-induced elevations in vasopressin in both male and female rats, our data supports a definite role for vasopressin in the anxiolytic actions of agomelatine. On the other hand, agomelatine treatment only reversed SIR-induced oxytocin deficits in female rats (*t*-test), thereby suggesting a lesser role for oxytocin in this regard, at least in the social isolation rearing model. Taken together, 5-HT~2C~ receptor antagonism by agomelatine may curb 5-HT-mediated vasopressin release, and in this way abrogate anxiety-like behavior ([@bibr13-0269881119826783]), a conclusion corroborated by a significant negative correlation between percentage TOA and vasopressin plasma levels. That said, it is possible that agomelatine may exert different dose-related effects on these neuropeptides with effects on corticosterone and oxytocin revealed at another dose. However, although 5-HT~2C~ antagonism is generally regarded as evoking an anxiolytic response ([@bibr7-0269881119826783]), agomelatine's short duration of receptor occupancy argues for another mechanism ([@bibr14-0269881119826783]).

Social isolation rearing is known to destabilize circadian rhythms ([@bibr11-0269881119826783]), while altered circadian fluctuation of the above neuropeptides has been described in chronic anxiety states, especially vasopressin ([@bibr20-0269881119826783]; [@bibr30-0269881119826783]). Considering the chronobiotic effect of agomelatine via the stimulation and block of MT~1~/MT~2~ and 5-HT~2C~ receptors in the suprachiasmatic nucleus respectively, agomelatine may modulate oxytocin and vasopressin release indirectly via re-synchronization of disordered neuropeptide rhythms following chronic stress ([@bibr23-0269881119826783]), or in this instance following social isolation rearing. The anxiolytic actions of agomelatine can thus be attributed to it reducing vasopressin and to a lesser degree increasing oxytocin. Since social isolation rearing emphasizes early life social distress as a central construct, and wherein oxytocin and vasopressin are noted to have a prominent role ([@bibr36-0269881119826783]), these actions offer a reasonable explanation for how agomelatine may exert anxiolytic-like effects in SIR rats.

Finally, our findings reveal a significant effect of sex on corticosterone in response to social isolation rearing but not with respect to oxytocin or vasopressin. Such sexual dimorphic responses have been suggested to explain the higher incidence of anxiety disorders and depression in women or antisocial behavior in males ([@bibr36-0269881119826783]). Agomelatine involves pronounced reversal of SIR-associated elevations in vasopressin in both females and males together with partial reversal of reduced oxytocin observed in females, but not males. Although both oxytocin and vasopressin have specific functions in males and females ([@bibr36-0269881119826783]), these effects may differ between the sexes ([@bibr3-0269881119826783]).

Conclusion {#section12-0269881119826783}
==========

Our combined data suggests that social isolation rearing is anxiogenic, with co-presentation of reduced plasma corticosterone and oxytocin and increased vasopressin, with a gender effect noted with respect to corticosterone. However, both sexes demonstrated significant association between anxiety-like behavior and elevated vasopressin. Furthermore, the anxiolytic-like effects of agomelatine involves a sex-independent reversal of SIR-associated elevations in vasopressin. This response was noted to a lesser extent with regard to oxytocin and only in female rats. As noted earlier ([@bibr43-0269881119826783]), corticosterone is not involved in this response. The anxiolytic response to agomelatine is likely to involve modulation of processes involved in vasopressin and oxytocin release, either via direct serotonergic and/or indirect chronobiotic mechanisms. This unique profile involving modulation of anxiety neuropeptides is of particular interest and warrants deeper study. Further study in other neurodevelopmental or genetic models is necessary to verify these findings.
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